<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03142204</url>
  </required_header>
  <id_info>
    <org_study_id>14-14488</org_study_id>
    <nct_id>NCT03142204</nct_id>
  </id_info>
  <brief_title>[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy</brief_title>
  <official_title>Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG (VisAcT), a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Cancer Patients Who Have Received or Are Expected to Receive Immunotherapy and/or Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellSight Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCSF Imaging Center at China Basin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CellSight Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study is to visualize biodistribution of a PET tracer called [18F]F-AraG
      (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory Phase 1, prospective study assessing the biodistribution and radiation
      dosimetry of the Positron Emission Tomography [18F]FAraG (VisAcT) in cancer patients selected
      for immunotherapy and/or radiation therapy. Each patient may have up to two [ 18F]FAraG PET
      imaging sessions, a baseline scan and a post start of immunotherapy scan. For each imaging
      session, patients will receive a single injection of [18F]FAraG and undergo a whole-body PET
      scans an hour after injection of the tracer. Following each imaging session, the patient will
      be called within 72 hours to note any side effects.

      Optional - Blood samples may be collected at up to 9 time points post-injection to analyze
      whole-blood/plasma time activity of [18F]FAraG in addition an urine sample may be collected
      post scan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visualize biodistribution of the PET tracer [18F]F-AraG pre-immunotherapy</measure>
    <time_frame>Up to 6 weeks before immunotherapy is administered</time_frame>
    <description>Whole-body [18F]F-AraG PET scan will be performed after intravenous injection of the PET tracer.consecutive time points the day of the intravenous injection of the PET tracer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visualize biodistribution of the PET tracer [18F]F-AraG post start of immunotherapy</measure>
    <time_frame>Up to 12 weeks after start of immunotherapy</time_frame>
    <description>Whole-body [18F]F-AraG PET scan will be performed after intravenous injection of the PET tracer.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]F-AraG</intervention_name>
    <description>Single dose IV injection of [18F]F-AraG for each imaging day.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer patients with identified tumor mass

          -  Cancer patients expected to undergo immunotherapy and/or radiation therapy

        Exclusion Criteria:

          -  Under the age of 18

          -  Pregnant women

          -  Women who are breastfeeding

          -  Individuals with known or suspected substance abuse

          -  Individuals unable or unwilling to comply with the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert R Flavell, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Department of Radiology &amp; Biomedical Imaging</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert R Flavell, M.D., Ph.D.</last_name>
    <phone>917-509-8679</phone>
    <email>robert.flavell@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henry VanBrocklin, Ph.D.</last_name>
    <phone>415-353-4569</phone>
    <email>henry.vanbrocklin@radiology.ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Imaging Center at China Basin</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Aslam</last_name>
      <phone>415-514-8987</phone>
      <email>maya.aslam@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katherine Wu</last_name>
      <phone>415-353-9437</phone>
      <email>katherine.wu@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

